{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T10:50:19Z","timestamp":1782730219545,"version":"3.54.5"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006586","name":"Centre Hospitalier Universitaire de Nice","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006586","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009242","name":"Direction generale de l'offre de soins","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009242","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.eclinm.2025.103648","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T08:43:12Z","timestamp":1763541792000},"page":"103648","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["The personalized approach to rituximab treatment in membranous nephropathy: a multi-center randomized controlled trial"],"prefix":"10.1016","volume":"90","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3357-5017","authenticated-orcid":false,"given":"Vesna","family":"Brglez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Teisseyre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K\u00e9vin","family":"Zorzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Cremoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Crepin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Lanot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Gueutin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Novel-Catin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Rigothier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Pelletier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Knebelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Chauveau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Audard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Halimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Verhelst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Cambiaggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Legueult","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Bailly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9rard","family":"Lambeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Esnault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Moranne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Seitz-Polski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.eclinm.2025.103648_bib1","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1056\/NEJM199307083290203","article-title":"Prognosis of untreated patients with idiopathic membranous nephropathy","volume":"329","author":"Schieppati","year":"1993","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103648_bib2","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/S0270-9295(03)00049-4","article-title":"Diagnosis and natural course of membranous nephropathy","volume":"23","author":"Glassock","year":"2003","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.eclinm.2025.103648_bib3","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.kint.2023.01.003","article-title":"Mapping antigens of membranous nephropathy: almost there","volume":"103","author":"Sethi","year":"2023","journal-title":"Kidney Int"},{"issue":"26","key":"10.1016\/j.eclinm.2025.103648_bib4","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1056\/NEJMoa012895","article-title":"Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies","volume":"346","author":"Debiec","year":"2002","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103648_bib5","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy","volume":"361","author":"Beck","year":"2009","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.eclinm.2025.103648_bib6","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1056\/NEJMoa1409354","article-title":"Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy","volume":"371","author":"Tomas","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103648_bib7","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.kint.2019.09.014","article-title":"Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy","volume":"97","author":"Sethi","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.eclinm.2025.103648_bib8","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1016\/j.mayocp.2023.08.006","article-title":"Mayo clinic consensus report on membranous nephropathy: proposal for a novel classification","volume":"98","author":"Sethi","year":"2023","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103648_bib9","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/ki.2012.486","article-title":"Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy","volume":"83","author":"Kanigicherla","year":"2013","journal-title":"Kidney Int"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103648_bib10","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1681\/ASN.2013040430","article-title":"Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy","volume":"25","author":"Hoxha","year":"2014","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"10.1016\/j.eclinm.2025.103648_bib11","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1681\/ASN.2010111125","article-title":"Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy","volume":"22","author":"Beck","year":"2011","journal-title":"J Am Soc Nephrol"},{"issue":"9981","key":"10.1016\/j.eclinm.2025.103648_bib12","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1016\/S0140-6736(15)60731-0","article-title":"Pathophysiological advances in membranous nephropathy: time for a shift in patient's care","volume":"385","author":"Ronco","year":"2015","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103648_bib13","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.kint.2021.05.015","article-title":"Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases","volume":"100","author":"Rovin","year":"2021","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103648_bib14","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1681\/ASN.2016040449","article-title":"Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up","volume":"28","author":"Dahan","year":"2017","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103648_bib15","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa1814427","article-title":"Rituximab or cyclosporine in the treatment of membranous nephropathy","volume":"381","author":"Fervenza","year":"2019","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103648_bib16","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1681\/ASN.2020071091","article-title":"Rituximab or cyclophosphamide in the treatment of membranous nephropathy: the RI-CYCLO randomized trial","volume":"32","author":"Scolari","year":"2021","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103648_bib17","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1053\/j.ajkd.2023.12.006","article-title":"Quantity versus quality of anti\u2013phospholipase A2 receptor 1 autoantibodies in the assessment of clinical outcome in membranous nephropathy: the debate continues","volume":"83","author":"Beck","year":"2024","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103648_bib18","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1681\/ASN.2014050502","article-title":"Identification of a major epitope recognized by PLA2R autoantibodies in primary membranous nephropathy","volume":"26","author":"Fresquet","year":"2015","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103648_bib19","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1681\/ASN.2013121315","article-title":"Identification of the immunodominant epitope region in phospholipase A2 receptor-mediating autoantibody binding in idiopathic membranous nephropathy","volume":"26","author":"Kao","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.eclinm.2025.103648_bib20","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1681\/ASN.2019030273","article-title":"Clinical relevance of domain-specific phospholipase A2 receptor 1 antibody levels in patients with membranous nephropathy","volume":"31","author":"Reinhard","year":"2020","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103648_bib21","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1681\/ASN.2014111061","article-title":"Epitope spreading of autoantibody response to PLA2R associates with poor prognosis in membranous nephropathy","volume":"27","author":"Seitz-Polski","year":"2016","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103648_bib22","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1681\/ASN.2017070734","article-title":"Phospholipase A2 receptor 1 epitope spreading at baseline predicts reduced likelihood of remission of membranous nephropathy","volume":"29","author":"Seitz-Polski","year":"2018","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103648_bib23","doi-asserted-by":"crossref","first-page":"6868","DOI":"10.1038\/s41598-025-91366-5","article-title":"Role of PLA2R domain antibodies and epitope spreading in risk stratification and prediction of proteinuria remission in primary membranous nephropathy","volume":"15","author":"Zhang","year":"2025","journal-title":"Sci Rep"},{"issue":"11","key":"10.1016\/j.eclinm.2025.103648_bib24","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1084\/jem.20022031","article-title":"The role of intramolecular epitope spreading in the pathogenesis of endemic pemphigus foliaceus (fogo selvagem)","volume":"197","author":"Li","year":"2003","journal-title":"J Exp Med"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103648_bib25","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/nri724","article-title":"Epitope spreading in immune-mediated diseases: implications for immunotherapy","volume":"2","author":"Vanderlugt","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.eclinm.2025.103648_bib26","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1084\/jem.182.1.75","article-title":"Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis","volume":"182","author":"McRae","year":"1995","journal-title":"J Exp Med"},{"issue":"12","key":"10.1016\/j.eclinm.2025.103648_bib27","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1681\/ASN.2007030342","article-title":"Intramolecular epitope spreading in Heymann nephritis","volume":"18","author":"Shah","year":"2007","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"10.1016\/j.eclinm.2025.103648_bib28","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.2215\/CJN.11791018","article-title":"High-dose rituximab and early remission in PLA2R1-related membranous nephropathy","volume":"14","author":"Seitz-Polski","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"issue":"20","key":"10.1016\/j.eclinm.2025.103648_bib29","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252011096","article-title":"Epitope spreading in immune-mediated glomerulonephritis: the expanding target","volume":"25","author":"Strizzi","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103648_bib30","doi-asserted-by":"crossref","first-page":"e0298269","DOI":"10.1371\/journal.pone.0298269","article-title":"Quantitative detection and prognostic value of antibodies against M-type phospholipase A2 receptor and its cysteine-rich ricin domain and C-type lectin domains 1 and 6-7-8 in patients with idiopathic membranous nephropathy","volume":"19","author":"Liu","year":"2024","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.eclinm.2025.103648_bib31","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1200\/JCO.2005.01.112","article-title":"Clinical trial designs for predictive marker validation in cancer treatment trials","volume":"23","author":"Sargent","year":"2005","journal-title":"J Clin Oncol"},{"issue":"August","key":"10.1016\/j.eclinm.2025.103648_bib32","doi-asserted-by":"crossref","first-page":"412","DOI":"10.3389\/fmed.2020.00412","article-title":"Personalized medicine for PLA2R1-related membranous nephropathy: a multicenter randomized control trial","volume":"7","author":"Brglez","year":"2020","journal-title":"Front Med"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103648_bib33","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)-A metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"10.1016\/j.eclinm.2025.103648_bib34","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/s41581-022-00564-1","article-title":"Membranous nephropathy: new pathogenic mechanisms and their clinical implications","volume":"18","author":"Hoxha","year":"2022","journal-title":"Nat Rev Nephrol"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103648_bib35","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41572-021-00303-z","article-title":"Membranous nephropathy","volume":"7","author":"Ronco","year":"2021","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103648_bib36","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1681\/ASN.2009080861","article-title":"Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy","volume":"21","author":"Polanco","year":"2010","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103648_bib37","doi-asserted-by":"crossref","first-page":"e0302100","DOI":"10.1371\/journal.pone.0302100","article-title":"Predictive value of the domain specific PLA2R antibodies for clinical remission in patients with primary membranous nephropathy: a retrospective study","volume":"19","author":"Zhou","year":"2024","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103648_bib38","doi-asserted-by":"crossref","first-page":"sfaf010","DOI":"10.1093\/ckj\/sfaf010","article-title":"Detection and prognostic relevance of PLA2R epitopes in idiopathic membranous nephropathy: a simultaneous quantitative multiplex suspension array detection method","volume":"18","author":"Wu","year":"2025","journal-title":"Clin Kidney J"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103648_bib39","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/j.ekir.2021.04.002","article-title":"Anti-PLA2R1 antibodies as prognostic biomarker in membranous nephropathy","volume":"6","author":"Logt","year":"2021","journal-title":"Kidney Int Rep"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025005826?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025005826?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T19:56:18Z","timestamp":1773863778000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537025005826"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":39,"alternative-id":["S2589537025005826"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103648","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The personalized approach to rituximab treatment in membranous nephropathy: a multi-center randomized controlled trial","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103648","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103648"}}